In a 60-year-old woman with atrial fibrillation and heart failure with preserved ejection fraction presenting with tachycardia and hypercholesterolemia, which medication should be added: amlodipine, atorvastatin, fenofibrate, hydrochlorothiazide, or metoprolol?

Metoprolol for Rate Control in Atrial Fibrillation with HFpEF

Add metoprolol to this patient's regimen to control her rapid ventricular rate and improve her symptoms of palpitations and dyspnea. 1, 2, 3

Rationale for Metoprolol as the Correct Answer

This 60-year-old woman presents with atrial fibrillation and rapid ventricular response (heart rate 125 bpm, irregularly irregular) causing symptomatic palpitations and dyspnea in the setting of HFpEF. Beta-blockers are the first-line rate-control agents for atrial fibrillation in patients with preserved ejection fraction, with metoprolol specifically recommended as a Class I option by both ACC and ESC guidelines. 4, 1, 2, 3

Why Rate Control is the Priority

• The patient's tachycardia (125 bpm) is directly causing her symptoms of palpitations and dyspnea on exertion, and controlling the ventricular rate will provide immediate symptomatic relief. 1, 2
• In HFpEF patients with atrial fibrillation, beta-blockers improve heart failure symptoms by slowing heart rate, prolonging diastolic filling time, and reducing left ventricular diastolic pressures. 4, 5
• Rate control targeting a heart rate <110 bpm is the appropriate initial strategy for this hemodynamically stable patient with new or worsening symptoms. 1, 2

Beta-Blocker Selection in HFpEF

• For patients with HFpEF (EF ≥50%) and atrial fibrillation, beta-blockers, diltiazem, or verapamil are all Class IIa recommendations to improve heart failure symptoms. 4, 2, 5
• Metoprolol and carvedilol are equally acceptable first-line beta-blockers for ventricular rate control in atrial fibrillation with preserved ejection fraction. 3
• Beta-blockers were the most effective drug class for achieving target heart rates in atrial fibrillation, reaching the goal in 70% of patients versus 54% with calcium-channel blockers. 3

Why the Other Options Are Incorrect

Amlodipine

• Amlodipine is a dihydropyridine calcium-channel blocker that has no role in rate control for atrial fibrillation; it provides vasodilation but does not slow AV nodal conduction. 1, 2
• This patient's blood pressure is already well-controlled at 130/70 mmHg, so additional antihypertensive therapy is not indicated. 4

Atorvastatin

• While the patient has hypercholesterolemia (total cholesterol 235, LDL 129), statin therapy does not address her acute symptomatic presentation of palpitations and dyspnea from rapid atrial fibrillation. 4
• Cardiovascular risk reduction with statins is important but secondary to controlling the symptomatic tachycardia that is impairing her quality of life. 6

Fenofibrate

• Fenofibrate is indicated for severe hypertriglyceridemia (typically >500 mg/dL); this patient's triglycerides of 140 mg/dL do not warrant fibrate therapy. 4
• Fenofibrate has no role in rate control or heart failure management. 4

Hydrochlorothiazide

• The patient has no evidence of volume overload on examination (lungs clear, no peripheral edema), so diuretic therapy is not indicated. 4, 6
• In HFpEF patients without congestion, diuretics should be used cautiously as excessive diuresis can reduce preload and worsen symptoms. 4, 5
• Thiazide diuretics have no role in rate control for atrial fibrillation. 1, 2

Implementation Strategy

Initial Dosing

• Start metoprolol tartrate 25-50 mg twice daily or metoprolol succinate 50-100 mg once daily, with gradual uptitration every 1-2 weeks based on heart rate response and tolerability. 3
• Target a resting heart rate of 60-100 bpm; rates up to 110 bpm are acceptable in stable patients. 1, 2

Monitoring Parameters

• Assess heart rate, blood pressure, and symptoms at each dose adjustment. 1, 2
• Monitor for signs of excessive bradycardia (<60 bpm), hypotension, or worsening dyspnea. 1
• Perform ambulatory ECG monitoring to assess 24-hour heart rate control if symptoms persist despite apparent rate control on office measurements. 4

Escalation if Monotherapy Fails

• If metoprolol alone does not achieve adequate rate control, add digoxin rather than switching to another agent; combination therapy provides superior rate control for both resting and exercise heart rates. 1, 3
• Oral amiodarone may be considered as a Class IIb option only when resting and exercise heart rates cannot be adequately controlled with metoprolol plus digoxin. 1, 3

Anticoagulation Consideration

• This patient requires stroke risk assessment using the CHA₂DS₂-VASc score; with age 60 years and heart failure, her score is at least 2, indicating a need for oral anticoagulation. 4, 1, 2
• Direct oral anticoagulants (DOACs) are preferred over warfarin due to lower intracranial hemorrhage risk. 2
• Anticoagulation should be initiated concurrently with rate control therapy. 4, 1, 2

Common Pitfalls to Avoid

• Do not use calcium-channel blockers (diltiazem, verapamil) as first-line in patients you suspect may have reduced ejection fraction, as they are contraindicated in HFrEF; beta-blockers are safe across the entire ejection fraction spectrum. 1, 2, 3
• Do not rely on digoxin as the sole rate-control agent in physically active patients, as it only controls resting heart rate and is ineffective during exercise. 1, 3
• Do not delay rate control to address cholesterol management; the patient's acute symptoms require immediate intervention. 6
• Do not add diuretics in the absence of volume overload, as this patient has clear lungs and no edema. 4, 6